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Abstract 
Background: The PI3K/Akt and the STAT3 pathways are functionally associated in many tumor types. Both in vitro 
and in vivo studies have revealed that either biochemical or genetic manipulation of the STAT3 pathway activity 
induce changes in the same direction in Akt activity. However, the implicated mechanism has been poorly character‑
ized. Our goal was to characterize the precise mechanism linking STAT3 with the activity of Akt and other AGC kinases 
in cancer using melanoma cells as a model.
Results: We show that active STAT3 is constitutively bound to the PDK1 promoter and positively regulate PDK1 tran‑
scription through two STAT3 responsive elements. Transduction of WM9 and UACC903 melanoma cells with STAT3‑
small hairpin RNA decreased both PDK1 mRNA and protein levels. STAT3 knockdown also induced a decrease of the 
phosphorylation of AGC kinases Akt, PKC, and SGK. The inhibitory effect of STAT3 silencing on Akt phosphorylation 
was restored by HA‑PDK1. Along this line, HA‑PDK1 expression significantly blocked the cell death induced by dac‑
arbazine plus STAT3 knockdown. This effect might be mediated by Bcl2 proteins since HA‑PDK1 rescued Bcl2, Bcl‑XL, 
and Mcl1 levels that were down‑regulated upon STAT3 silencing.
Conclusions: We show that PDK1 is a transcriptional target of STAT3, linking STAT3 pathway with AGC kinases activity 
in melanoma. These data provide further rationale for the ongoing effort to therapeutically target STAT3 and PDK1 in 
melanoma and, possibly, other malignancies.
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Background
The transcription factor Signal Transducer and Activa-
tor of Transcription 3 (STAT3) shows low or null activity 
in normal unstimulated cells but an enhanced activity in 
various types of human cancer cells. Compelling evidence 
has established that aberrant STAT3 activity has a criti-
cal role in the development and progression of human 
tumors by promoting uncontrolled cell proliferation and 
growth, cell survival, induction of angiogenesis, and the 
suppression of host immune surveillance [1, 2].
Melanoma is a highly aggressive skin cancer whose 
incidence has been rising substantially over the last few 
decades worldwide [3]. If diagnosed early, melanoma is 
curable by surgical resection. However, the prognosis of 
metastatic melanoma is poor with a 5-year survival rate 
lower than 20%. Malignant melanoma is a difficult can-
cer to treat given its resistance to chemotherapy and 
radiotherapy [4]. Targeting of the prevalent BRAF V600E 
mutation (present in around 50% of patients) with vemu-
rafenib or similar compounds produce clinical responses 
in most melanoma patients but all patients develop 




*Correspondence:  pablobergami@gmail.com 
2 Centro de Estudios Biomédicos, Biotecnológicos, Ambientales y 
Diagnóstico (CEBBAD), Universidad Maimónides, CONICET, Hidalgo 775, 
6th Floor, Lab 602, Buenos Aires, Argentina
Full list of author information is available at the end of the article
Page 2 of 14Picco et al. Cell Biosci             (2019) 9:3 
A large body of evidence has implicated hyperactive 
receptor tyrosine signaling in the development and pro-
gression of melanoma. These include mutations on KIT, 
ERBB4, the EPH and FGFR families, genomic amplifica-
tion of EGFR and PDGRFA among others [6]. Therefore, 
it is not surprising that STAT3, being a point of con-
vergence of many of these signaling pathways, has been 
found to be activated at high frequency and has been 
implicated in melanoma progression [7–9]. The levels of 
p-STAT3 is higher in metastasis (particularly brain and 
lung) than in cutaneous primary melanomas [9, 10]. Also, 
p-STAT3 expression is a negative prognostic factor for 
overall survival in patients that did not develop central 
nervous system metastasis [9, 10]. Recent pieces of evi-
dence have shown that STAT3 activation is an important 
mechanism of resistance to targeted therapies against 
mutant BRAF, a critical oncogene in melanoma [11–14]. 
Many of the above-mentioned alterations result in a per-
sistent phosphorylation of STAT3 at Tyrosine 705  (Y705) 
and STAT3-dependent transactivation of target genes 
through binding of STAT3 dimers to consensus STAT3 
binding sequences on their promoters [15]. A large num-
ber of genes whose transcription is regulated by STAT3 
have been identified (i.e. Cyclin D1/D2, c-Myc, p21WAF, 
VEGF, Mcl-1 and Bcl-xL) [16]. However, evidence from 
microarray and ChIP-seq studies have revealed that a 
large number of potential STAT3 target genes remains to 
be characterized [17–20]. Since STAT3 is emerging as a 
target of interest for many cancers it is essential to iden-
tify novel STAT3 target genes that will help understand 
the pleiotropic functions of STAT3 in tumorigenesis.
In the present work, we studied a new transcriptional 
target of STAT3, phosphoinositide-dependent kinase 1 
(PDK1). PDK1 is the master regulator of at least 23 other 
AGC kinases whose downstream signaling has often 
been implicated in various diseases and particularly in 
cancer [21]. The AGC is a large group of protein kinases 
(more than 60) named after the protein kinase A, G, and 
C families (PKA, PKG, PKC). To be active, these kinases 
require phosphorylation at both the activation loop and 
the hydrophobic domain (e.g.  Thr308 and  Ser473 for Akt1, 
by PDK1 and mTORC2, respectively) [22]. Several mech-
anisms contribute to the constitutive activity of many 
AGC kinases in melanoma. For example Akt, one of the 
prominent members of this family, is constitutively acti-
vated by the concurrent effect of Ras mutations or PTEN 
loss, Akt amplification and active-functioning autocrine 
loops [8]. PDK1 itself has been recognized to have an 
important role in cancer [22]. In melanoma, PDK1 has 
been implicated in disease development and progres-
sion through regulation of Akt, SGK3 and FOXO3a [23, 
24]. For this reason, great efforts have been dedicated to 
understanding how PDK1 itself is regulated and how, in 
turn, regulates its different substrates spatially and tem-
porally. Unlike the other kinases in the AGC family, PDK1 
is autophosphorylated [25] meaning that, for the most 
part, its function is not regulated by an upstream kinase 
but by alternative mechanisms like protein–protein 
interaction, conformational rearrangements, changes in 
subcellular localization or at the transcriptional level [26, 
27]. The present work describing the STAT3-dependent 
regulation of PDK1 offers important new insights into 
the mechanism underlying STAT3 oncogenic activity 
through feeding into AGC kinase activity.
Methods
Cell culture
Melanoma lines were kindly provided by Dr. M. Her-
lyn and Dr. Z. Ronai. All cell lines were maintained in 
DMEM supplemented with 10% fetal bovine serum (FBS, 
Gibco) 100 U/ml penicillin and 100 mg/ml streptomycin 
(Invitrogen), at 37  °C and 5%  CO2. Cell lines were vali-
dated in 2016 by short tandem repeat analysis (STR) of 
extracted genomic DNA using GenePrint 10 System, Pro-
mega, according to manufacturer instructions. Cells were 
transfected with calcium phosphate or by Lipofectamine 
PLUS reagent (Invitrogen) following the manufacturer’s 
protocol.
Viral constructs
The oligonucleotides targeting STAT3 (5′-GCA GCA 
GCT GAA CAA CAT G-3′ and 5′-GAT TGA CCT AGA 
GAC CCA C-3′) [28] and scramble (5′-GAA ACT GCT 
GAC CGT TAA T-3′) were cloned into pRetroSuper vec-
tor. To generate the viral particles, HEK-293T producer 
cells were cotransfected with the retro vectors and the 
packaging plasmids. Viral supernatants were harvested, 
filtered and used to transduce WM9 and UACC903 cells. 
Cells were selected in 3 µg/ml puromycin for 1 week and 
then maintained with 1  µg/ml puromycin. WT PDK1 
cDNA together with a HA tag was cloned into pBABE-
Hygro as described [26]. This vector was introduced into 
WM9 cells in the same manner and transduced cells were 
selected with 100 μg/ml Hygromycin B (Gibco).
Real time PCR
Real time PCR was performed as described [27]. Specific 
primers used for PCR were as follows: PDK1 forward 
5′GTC TTA TCC CCA GAG AGC AAAC3′; PDK1 reverse, 
5′AGC AGC TCT GGA GAA ACG TACT3′, RNPII for-
ward 5′GCT GTG TCT GCT TCT TCT G3′, RNPII reverse 
5′CGA ACT TGT TGT CCA TCT CC3′ RNA polymerase II 
(RNPII) served as an endogenous control. Reactions were 
run in triplicate. The target mRNA concentration of con-
trol cells, normalized to the level of RNPII mRNA, was 
set to 1.
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Chromatin immunoprecipitation (ChIP)
For ChIP analysis, WM9 cells were fixed with 11% for-
maldehyde and sheared chromatin was immunopre-
cipitated with a STAT3 antibody (sc-482, Santa Cruz 
Biotechnology) or control IgG and subjected to real-
time PCR. The following primers corresponding to the 
proximal region of the PDK1 promoter were used: PDK1 
forward 5′GAG CCT GGT CCC CTC TGA 3′ and PDK1 
reverse 5′GAT TGG TTC GCG CGA GGT 3′.
Trypan blue exclusion assay
The WM9 cells were seeded on 24-well plates at a den-
sity of 4 × 104 cells per well and incubated for 24  h to 
adhere. Cells were exposed to 100  μg/ml dacarbazine 
(dissolved in PBS) or PBS as a control for 72 h. After that 
time point, both the adherent and floating cells were col-
lected, mixed with trypan blue and the number of viable 
cells was counted using a haemocytometer. The percent-
age of non-viable cells regarding the total number of cells 
was calculated. Each treatment was performed in dupli-
cate and three independent experiments were performed. 
Error bars represent the standard errors.
Resazurin assay
To study relative cell viability, 3000 cells per well were 
seeded (in 100 μl volume of DMEM minus phenol red) in 
96-well microplates in eight-duplicates. After 24 h, cells 
were treated with 100 μg/ml dacarbazine for 72 h. Then, 
Rezasurin (Cayman Chemical), the active compound of 
the commercially available dye Alamar Blue (Bio-Rad), 
was added at a final concentration of 0.4  mM and the 
plates were incubated for 4 h at 37C. The absorbance at 
570  nm and 600  nm was determined in a Biotek plate 
reader. A standard curve with different cell densities was 
prepared in a parallel plate. To determine the differences 
in cell viability between treated and control cells we fol-
lowed the calculations described by the Alamarblue cyto-
toxicity assay kit (Bio-Rad).
Quantification of apoptotic cell death
The WM9 and UACC903 cells were seeded on 6-well 
plates at a density of 1.25 × 105  cells per well. The fol-
lowing day they were exposed to 100 μg/ml Dacarbazine 
(or PBS as a control) for 72  h. Cells were washed twice 
with PBS and resuspended in 100 µl of Annexin V bind-
ing buffer (pH 7.4) (BD Biosciences, Franklin Lakes, 
NJ, USA). Then, Annexin V-Alexa Fluor 488 (BD Bio-
sciences) was added and incubated for 15 min under dark 
conditions. Propidium iodide (0.1 µg/ml; Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany) was added just prior 
to signal acquisition. Cells were analyzed using a FAC-
SAria flow cytometer (BD Biosciences) and analyzed with 
FACSDiva 7.6.1 software (BD Biosciences).
Flow cytometry
Single-cell suspensions were fixed (4% PFA) and per-
meabilized (PBS, 0.5% saponin, 10% FBS). Cells were 
incubated with primary antibodies or respective isotype 
controls for 30  min at 4  °C. Unconjugated Antibod-
ies to PDK1 (3062), P-Akt (Thr308, 9275 and 2965), Akt 
(2967 and 9272), pan-P-PKC (9371) from Cell Signaling 
and Akt (sc-5298) and PKCβ (sc-210), from Santa Cruz 
Biotechnologies were used. Preimmune rabbit sera or 
isotype matched mouse Ig were used as a control. FITC-
conjugated goat anti-mouse or anti-rabbit Ig was added 
for 30  min at RT in the dark. Cells were acquired on a 
FACSAria flow cytometer (BD Biosciences) and analyzed 
using Cyflogic software. The protein level is quantified as 
the mean fluorescence intensity (MFI) after subtraction 
of control Ab MFI.
Luciferase assays
The PDK1 promoter reporter plasmids were generated as 
described [26]. Site-directed mutagenesis of STAT3 sites 
were performed using the QuikChange II kit (Stratagene) 
following the manufacturer’s protocol. Cell lysates were 
prepared from lipofectamine-transfected cells after 24 or 
48 h. Luciferase activity was measured with the luciferase 
assay system (Promega) in a luminometer and was nor-
malized with β-galactosidase activity. Results are shown 
as the mean (bar) ± S.D.
Western blotting
For the Western blotting analysis, cell lysates were col-
lected by addition of lysis buffer supplemented with 
protease and phosphatase inhibitors for 10 min on ice 
[29]. The cell lysates were centrifuged at 13,000  rpm 
for 15 min at 4 °C, and the supernatants were collected 
and quantified using the Bradford method. Between 
20 and 50  μg of proteins were diluted in 6× Laemmli 
buffer, boiled at 95 °C for 5 min, separated on 10–12% 
SDS-PAGE gels and then transferred to nitrocellu-
lose membrane. The membranes were blocked with 
5% milk in 0.05% Tween-PBS at room temperature 
for 1  h and then incubated with the primary antibod-
ies at 4  °C overnight. The following antibodies were 
used: Akt1 (sc-5298), p-Akt (sc-7985), GAPDH (sc-
25778), STAT3 (sc-482), pSTAT3 (sc-8059), PKCb (sc-
210), Vimentin (sc-73614), Mcl-1 (sc-819) and Bcl-XL 
(sc-634) from Santa Cruz Biotechnologies. Antibodies 
to PDK1 (3062), P-PDK1 (3061), P-Akt (Thr308, 9275 
and 2965), Akt (2967 and 9272), pan-P-PKC (9371), 
pSGK (T256, 2939), SGK (12103) and Bcl-2 (2876) 
were from Cell Signaling. Antibodies to Actin (A5441) 
and Tubulin (T9026) were from Sigma. Because PKC 
autophosphorylation at the hydrophobic site depends 
on the efficiency of activation loop phosphorylation by 
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PDK1, we used the P-PKC (Ser660) antibody to moni-
tor activation loop phosphorylation. The correspond-
ing HRP-conjugated secondary antibodies: anti-mouse 
(GE NA931V), anti-rabbit (GE NA934) or anti-goat 
(sc-2020) were incubated for 1 h at room temperature. 
Immunoreactive bands were detected by an ECL sys-
tem (Amersham Biosciences) using an image reader 
(ImageQuant 350, GE Healthcare). Quantification of 
band intensities was performed using ImageJ (NIH). 
The intensity of each band was normalized to GAPDH 
or other housekeeping gene (i.e. Tubulin or Actin) and 
the Fold Change (FC) relative to control cells was cal-
culated. The band intensities in the phosphoprotein 
blots were normalized with those of the total proteins 
obtained from the same blots after stripping and rep-
robing. To draw conclusion on a particular experiment 
at least three biological (independent) replicates of 
paired samples were examined to calculate the mean 
and standard deviation. The log transformation of FC 
values were calculated to obtain a more symmetric dis-
tribution that better suits the normality assumptions of 
the subsequent t-test.
Statistics
Except when indicated, experiments were performed 
at least three times. All data are expressed as the 
mean ± SD. Mean differences between groups were 
determined using Student’s T tests or one-way ANOVAs 
followed by  post hoc tests. Values of p < 0.05 were con-
sidered statistically significant. Statistical analyses were 
conducted using software from Graph-Pad Prism. The 
number of independent experiments and specific statisti-
cal analyses used in each experiment are indicated in the 
figure legends.
Results
STAT3β negatively regulates PDK1 expression
During experiments addressing STAT3’s role in tumo-
rigenesis, we observed that SW1 mouse melanoma cells 
transduced with STAT3β presented a marked reduction 
in the levels of PKC phosphorylated at the hydrophobic 
motif  (Ser660 in PKCβII) (Fig.  1a). STAT3β is a STAT3 
splice variant usually seen as a natural dominant nega-
tive form [30]. Since the hydrophobic motif of PKC is 
autophosphorylated subsequently to phosphorylation on 
the activation loop  (Thr500 in PKCβII) by PDK1 [31], we 
analyzed changes in PDK1 levels in these cells. As shown 
in Fig. 1b, expression of STAT3β markedly decreased the 
expression of PDK1 (Fig.  1b). These data suggest that 
STAT3β might interfere with a positive regulation of 
PDK1 expression by STAT3.
STAT3 regulation of PDK1 modulates phosphorylation 
of AGC kinases
To study this mechanism in human melanoma cells 
using a suitable model we screened several melanoma 
cell lines to identify those displaying constitutive STAT3 
activation. Phosphorylation of  Tyr705, a marker of STAT3 
activation, was detected in several cell lines (Fig.  2a), 
regardless of BRAF status, since all the cell lines except 
for Mewo are mutant for BRAF. We then used the tyros-
ine kinase inhibitor SKI-606 to inhibit STAT3 phos-
phorylation in WM9, one of the cell lines that showed 
constitutive STAT3 activity (Fig.  2b). Similar to what 
we observed in mouse cells, inhibition of STAT3 activ-
ity using SKI-606 resulted in a decrease on PDK1 levels 
(Fig.  2b). To further explore the regulation of PDK1 by 
STAT3 we employed RNA interference (RNAi) to knock-
down STAT3 expression in cultured cell lines. To rule out 
nonspecific effects of the technique, two STAT3 specific 
pRetroSuper-based shRNAs (short-hairpin RNA) labeled 
shSTAT3-I and -II, were transduced into both WM9 
and UACC903 cells. As a control, cells were transduced 
with a shRNA containing a scramble sequence. West-
ern blots showed that the two shRNA very efficiently 
knockdown STAT3 expression (Fig. 2c, d). In agreement 
with our previous results, STAT3 silencing in WM9 and 
UACC903 cells induced a decrease in PDK1 protein lev-
els (Fig.  2c, d). The decrease in PDK1 was statistically 
significant as demonstrated by quantification of West-
ern blots from three independent biological replicates 
(Fig. 2c, d). Flow cytometry analysis confirmed a signifi-
cantly lower expression of PDK1 in UACC903 cells upon 
STAT3 silencing relative to control cells (Fig. 2e).
As seen in mouse cells, inhibition of STAT3 in both 
WM9 and UACC903 cell lines significantly reduced 
P-PKC levels, as established by quantification of Western 
Fig. 1 STAT3β negatively regulates PKC phosphorylation and PDK1 
expression. Protein extracts from SW1 cells stably transfected with 
STAT3β or empty vector (−) were blotted with P‑PKC and PKCβII 
antibodies (a) and PDK1 antibodies (b). Tubulin and actin were used 
as loading control. The blots displayed are representative of three 
independent experiments
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blot data (Fig.  3a). Since PDK1 is a master kinase that 
regulates the activity of several protein kinases we eval-
uated whether STAT3-dependent regulation of PDK1 
affected phosphorylation of other AGC family kinases 
such as Akt and SGK. STAT3 knockdown significantly 
decreased phosphorylation of  Thr308 of Akt, an indispen-
sable event in Akt activation [31] in both UACC903 and 
WM9 cell lines as determined by quantitative analysis of 
five biological replicas by Western blot (Fig.  3b). Total 
Akt levels were not affected. Likewise, STAT3 silencing 
prevented SGK activation by inhibiting phosphoryla-
tion of  Thr256 at its activation loop (Fig.  3c). Although 
the decrease in P-PKC and P-Akt levels was significant 
and consistently observed, we wanted to further docu-
ment these changes using a fully quantitative and more 
sensitive technique such as Flow cytometry. The analysis 
performed confirmed that STAT3 silencing significantly 
reduced the level of P-PKC (Ser660) and P-Akt (Thr308) 
in UACC903 cells (Fig.  4a, c). In these experiments we 
also determined that phosphorylation of Akt at Ser473 
was also significantly inhibited by STAT3 knockdown 
(Fig. 4d), confirming the impairment of the Akt activity. 
This technique also confirmed that total Akt and PKCβ 
levels were not affected by STAT3 silencing (Fig.  4b, e). 
To confirm these findings using an alternative approach 
we stably transfected WM115 cells (that do not present 
Fig. 2 Silencing of STAT3 reduced PDK1 expression. a Activation of STAT3 in melanoma cell lines. Western blot analysis of STAT3 and P‑STAT3 levels 
in human melanoma cell lines. b STAT3 inhibition by SKI‑606 reduced PDK1 expression. WM9 cells were treated with 1 uM SKI‑606 (SKI) for 8 h. 
Protein extracts were blotted with the indicated antibodies. PDK1 levels were normalized to the loading control and expressed as the fold change 
(FC, numbers below the blots) relative to DMSO‑treated cells. c, d Silencing of STAT3 in WM9 (c) and UACC903 (d) cells reduced PDK1 expression. 
Cells were transduced with retrovirus encoding two STAT3 shRNA (I and II) and a scramble sequence as a control. Protein extracts were probed with 
STAT3, PDK1 and GAPDH or Actin as a loading control. The blots displayed are representative of three independent experiments. Bar graphs show 
the mean ± S.D. (from three independent experiments) of PDK1 levels normalized to the loading control and expressed as the fold change (FC) 
relative to scramble cells. Statistical significance was tested by one‑tailed Student’s T‑Test using log transformed FC values. *p < 0.01, n = 3. e Flow 
cytometry analysis of PDK1 expression. Cells were collected and stained as described in “Methods”. Light‑grey filled histogram correspond to control 
(preimmune) Ab and open histograms to PDK1 ab. The MFI (Mean Fluorescence Intensity) was detected by flow cytometry. Bar graph shows the 
mean PDK1 MFI ± S.D. (from three independent experiments). Statistical significance was tested by a one‑tailed Student’s T‑Test. ***p < 0.0001, n = 3. 
The blots and histogram displayed are representative of three independent experiments
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Fig. 3 STAT3 silencing reduced PKC, Akt, and SGK phosphorylation. Protein extracts from WM9 and UACC903 cells described in Fig. 2. were 
assayed in Western blot to determine PKC a, Akt b and SGK c phosphorylation. a, b A P‑Pan‑PKC antibody against Ser660 was used. Total PKC was 
estimated by using a PKCβII antibody. Tubulin, Vinculin and Actin were used as loading controls. The blots displayed are representative of three 
independent experiments. Bar graphs show the mean ± S.D. (from three independent experiments) of P‑PKC a and P‑Akt b levels normalized to 
the corresponding total protein level and expressed as the fold change relative to scramble cells. Statistical significance was tested by one‑tailed 
Student’s T‑Test using log transformed FC values. *p < 0.01, n = 5. c WM9 extracts described above were probed with the indicated antibodies. 
Protein levels after STAT3 silencing were normalized to the corresponding total protein level and expressed as the fold change (numbers below the 
blots) relative to scramble cells. The blots displayed are representative of two independent experiments. d STAT3C increased P‑Akt levels. Protein 
extracts from WM115 cells stably transfected with STAT3C were probed with the indicated antibodies. GAPDH was used as a loading control. 
Bar graph shows the mean ± S.D. (from three independent experiments) of P‑Akt levels normalized to the corresponding total protein level and 
expressed as the fold change relative to Empty cells. Statistical significance was tested by one‑tailed Student’s T‑Test using log transformed FC 
values. *p < 0.01, n = 3
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STAT3 phosphorylation, Fig. 2a) with STAT3C, a consti-
tutively active STAT3 mutant with two Cys substitutions 
that enable STAT3 molecules to dimerize spontaneously 
without phosphorylation at Y705 [1]. In agreement with 
previous data, expression of STAT3 induced an increase 
in P-Akt (Ser473) levels (Fig.  3d). We did not observed 
changes in P-PKC (Pan) in these cells. Altogether, these 
results indicate that STAT3 regulates PDK1 expression 
and modulates Akt, PKC and SGK activity.
STAT3 binds human PDK1 promoter and activates PDK1 
transcription
The data above showed a reduction of PDK1 protein lev-
els in STAT3 deficient cells. Real-Time PCR experiments 
revealed that STAT3 silencing in both WM9 and 
UACC903 cells also led to a significant decrease in PDK1 
mRNA levels (Fig. 5a) suggesting that STAT3 could reg-
ulate PDK1 levels through direct transactivation of its 
promoter. To study this possibility we performed in sil-
ico analysis of the DNA sequence 1-kb upstream of the 
human PDK1 transcription start site, a region that pre-
sent Histone 3 modification patterns typical of enhancer 
elements (UCSC genome browser, data not shown). 
In this region, we looked for putative STAT3 respon-
sive elements (SRE) using ECR Browser and rVista 2.0, 
loaded with the Transfac 10.2 matrix library [32]. Using 
a matrix similarity cut-off of 0.9, the analysis found 7 
potential SRE starting at positions − 909, − 440, − 365, 
Fig. 4 Flow Cytometry analysis of total and activated PKC and Akt upon STAT3 silencing. a Flow cytometry analysis of P‑PKC a, PKCβ b, P‑Akt 
(T308) c, P‑Akt (S473) d and Akt e expression. Cells were collected and stained as described in “Methods”. Light‑grey filled histogram correspond to 
control Ab and open histograms to the corresponding specific abs. Solid and broken lines correspond to scramble and shSTAT3 cells, respectively. 
Bar graphs show the mean mean fluorescence intensity (MFI) ± S.D. (from three independent experiments) for the indicated antibody. Statistical 
significance was tested by a one‑tailed Student’s T‑Test, ***p < 0.0001, ns: not significant, n = 3
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Fig. 5 STAT3 binds to the PDK1 promoter and regulates its transcription. a STAT3 silencing decreased PDK1 mRNA levels. Relative levels of PDK1 
mRNA were determined by Real‑Time PCR in both UACC903 and WM9 cells stably transduced with two STAT3 shRNA targeting sequences. mRNA 
levels were normalized to internal RNPII levels and expressed as relative to control cells. For WM9 cells, the mean ± S.D. from three independent 
experiments is shown. *p < 0.05. For UACC903 cells, the mean ± S.D. from one representative experiment out of two is shown. b Structure of the 
proximal region of the human PDK1 promoter. Putative STAT3 responsive elements (in grey) and fragments of the promoter that were cloned 
into pGL2 are depicted. The sites at − 265 and − 137 were removed by mutagenesis. c Silencing of STAT3 diminishes the reporter activity of 
the PDK1 promoter. The indicated reporter plasmids were transfected into UACC903‑shSTAT3 and UACC903‑scramble cells. Results are shown 
as the mean ± S.D. *p < 0.05. **p< 0.01. d Active STAT3 induced luciferase activity driven by the PDK1 promoter. The plasmid − 410/+ 82 was 
co‑transfected into WM115 cells together with STAT3β and STAT3C plasmids. Results are shown as the mean ± SD. **p < 0.01. e STAT3 silencing 
decrease binding of STAT3 to the PDK1 promoter. The plot shows the relative level of PDK1 amplification (normalized to GAPDH levels) following a 
Chromatin immunoprecipitation assay on UACC903‑shSTAT3 and UACC903‑scramble cells. The mean ± S.D. from three independent experiments is 
shown. *p < 0.05. f STAT3 enhances PDK1 transactivation through the SREs at − 265 and − 137. Reporter plasmids described in b were transfected 
into UACC903‑shSTAT3 and UACC903‑scramble cells. Results are shown as the mean ± S.D. *p < 0.001, Student’s t‑Test; the activity of the mutant 
promoters was compared to that of − 410/+ 82 fragment. #p < 0.001, ANOVA followed by Dunnett’s Multiple Comparison Test
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− 282, − 265, − 137 and − 38 of the human PDK1 pro-
moter. Thus, we cloned this region of the human PDK1 
promoter (1053  bp) into a luciferase reporter plasmid 
and generated a series of truncated constructs that are 
represented in Fig. 5b. After transfection into UACC903 
control cells (UACC903-scramble), the three larger pro-
moter fragments (− 971/+ 82, 536/+ 82 and − 410/+ 82) 
displayed a high degree of activity (more than 300 times) 
over the baseline control construct containing only the 
luciferase gene (Fig.  5c). Among the three larger pro-
moter fragments, 971/+ 82 and − 410/+ 82 showed the 
lowest and higher promoter activity, respectively. Impor-
tantly, the three promoter fragments elicited a reduced 
luciferase activity when transfected into UACC903 sta-
bly expressing STAT3 shRNA (UACC903-shSTAT3) 
compared to the scramble control (UACC903-scramble) 
(Fig.  5c). On the contrary, the shortest promoter frag-
ment (− 131/+ 82) showed similar luciferase activity both 
in UACC903-shSTAT3 and UACC903-scramble cells. 
Similar results were obtained when the reporter plasmids 
were cotransfected with STAT3β (Additional file  1: Fig-
ure S1). The similar response elicited by the three larger 
promoter fragments suggest the functional SRE is situ-
ated in the region between nucleotides − 410 and − 131. 
These experiments could not be performed in WM9 
cells since these cells are poorly transfectable. We next 
examined whether increased levels of activated STAT3 
induce luciferase activity driven by the PDK1 promoter. 
To investigate this possibility, we cotransfected WM115 
cells with the − 410/+ 82 fragment together with 
STAT3C. Figure 5d shows that transfection with STAT3C 
but not STAT3β, increased reporter activity driven by 
the − 410/+ 82 fragment (Fig. 5d). These results further 
point to the presence of one or more SRE in the PDK1 
promoter region from − 410 to − 131.
Further support for the role of STAT3 in the regulation 
of PDK1 transcription comes from ChIP analysis. To this 
end, sheared chromatin was immunoprecipitated with 
antibodies to STAT3 (or control IgG) followed by Real-
Time PCR amplification of PDK1 promoter sequences 
bearing putative SRE. Immunoprecipitation of STAT3 
enabled amplification of a DNA fragment corresponding 
to a region from − 300 to − 177 of the PDK1 promoter, 
demonstrating in  vivo binding of STAT3 to the PDK1 
promoter. Silencing of STAT3 reduced the amount of 
DNA amplified from the chromatin after STAT3 immu-
noprecipitation to values similar to those observed after 
immunoprecipitation with control IgG (Fig. 5e).
The data above showed that STAT3 mediates PDK1 
transcription through a region of 279 nucleotides from 
− 410 to − 131 that has four putative SRE (Fig. 5b). Fol-
lowing a further analysis of this region using oPOSSUM 
[33], we narrowed down the candidate sites to the ones 
starting at − 265 and − 137, which displayed the high-
est scores. To precisely identify the functional SREs 
on the PDK1 promoter, the reporter assays were per-
formed using the − 410/+ 82 vectors harboring muta-
tions that destroyed the SREs at − 265 and − 137 sites 
of the PDK1 promoter. Mutation of either of these sites 
reduced the reporter activity in UACC903-scrambled 
cells compared to the wild-type promoter (Fig.  5f ). In 
line with this data, the simultaneous mutation of both 
sites drastically reduced the luciferase activity (Fig.  5f ). 
Silencing of STAT3 further reduced the activity of each 
promoter fragment indicating that the mutant reporters 
are still transactivated by STAT3. In contrast, the activ-
ity driven by the double mutant promoter was similar in 
both UACC903-scramble and UACC903-shSTAT3 cells 
indicating that this promoter fragment had completely 
lost STAT3 responsiveness (Fig.  5f ). Altogether, these 
results indicate that STAT3 transactivates PDK1 through 
two SRE located at − 265 and − 137. Interestingly, nei-
ther of the two SRE displays the canonical sequence 
 TTCN2–4GAA. However, the site at − 265 (TGC CGG 
AA) displays two half-sites (TGC and GAA) that are 
identical to the ones described on the SRE of IL10 [34], 
GADD45B [35] and STAT3 [36]. The site at -137 (AAC 
CCG GAA) present similarities with the SRE of LBP 
(CAC TGG GAA, one mismatch on the 5′ half-site, [37]) 
and with two SRE of Gamma Fibrinogen (site II, ATC 
GGC GAA and site III, GAC TGG GAA, both displaying 
one mismatch on the 5′ half-site, [38]). Taken together, 
these results demonstrate a direct interaction between 
activated STAT3 and regulatory elements of the PDK1 
gene and suggest direct transcriptional regulation of 
PDK1 by STAT3.
PDK1 partly rescues cell death triggered by dacarbazine 
treatment and STAT3 silencing
We next proceeded to address the biological significance 
of the STAT3-PDK1 connection. To this end, we rescued 
the expression of PDK1 in STAT3 knockdown cells by 
stable transducing WM9-scramble and WM9-shSTAT3 
cells with a retrovirus expressing HA-tagged PDK1 or 
empty vector (Fig. 6a). As shown before, STAT3 silencing 
significantly inhibited S473 Akt phosphorylation (lane 2). 
Expression of HA-PDK1 increased P-Akt levels in scram-
ble cells (lane 3) and restored P-Akt levels in STAT3 
knockdown cells (lane 4) to levels slightly above to those 
of control cells (lane 1)(Fig. 6a).
In recent years, several articles have pointed out the 
important role of STAT3 inhibition in apoptosis in mela-
noma [39–41]. However, STAT3 silencing did not altered 
neither cell proliferation (Additional file 2: Figure S2) nor 
cell death under normal growing conditions (see below) 
likely due to pathway redundancy. For the STAT3’s role in 
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Fig. 6 PDK1 mediates STAT3’s effect on melanoma cell survival. a Reconstitution of PDK1 upon STAT3 silencing rescued Akt phosphorylation. 
WM9‑scramble and WM9‑shSTAT3 cells were stably transduced with HA‑PDK1. Protein extracts were probed with STAT3, P‑Akt, Akt, HA and 
GAPDH as a loading control. The blots displayed are representative of three independent experiments. Bar graphs show the mean ± S.D. (from 
three independent experiments) of P‑Akt levels normalized to total Akt and expressed as the fold change relative to scramble/pBH cells (Control). 
Statistical significance was tested by one‑tailed Student’s T‑Test using log transformed FC values. **p < 0.001, ns: not significant, n = 5. b–e PDK1 
reconstitution prevents dacarbazine‑induced cell death in STAT3 knockdown cells. The cells were treated with dacarbazine (100 μg/ml) for 72 h. 
b Viability was determined by the Trypan Blue exclusion assay. Bar Graph shows the mean ± S.D. (from three independent experiments) of the 
percentage of non‑viable cells. Statistical significance was tested by ANOVA followed by Tukey’s Multiple Comparison Test. *p < 0.01 **p < 0.001, ns: 
not significant, n = 3. c Viability was determined by the Resazurin assay. Bar Graph shows the mean ± S.D. (from three independent experiments) 
of the percentage of non‑viable cells. Statistical significance was tested by ANOVA followed by Tukey’s Multiple Comparison Test. *p < 0.01 
**p < 0.001, ns: not significant, n = 3. d, e WM9 (d) or UACC903 (e) cells were treated with dacarbazine, stained with PI/Annexin V and analyzed 
by Flow cytometry. Representative histograms are shown. The ratio of dead/live cells from three biological replicates ± S.D is shown below. Live 
cells correspond to cells in the lower left quadrant and dead cells are the sum of the other three quadrants. Statistical significance was tested by 
ANOVA followed by Tukey’s Multiple Comparison Test. *p < 0.01 **p < 0.001, ns: not significant, n = 3. f PDK1 mediates STAT3’s effect on expression of 
anti‑apoptotic proteins. Protein extracts from WM9‑scramble and WM9‑shSTAT3 cells stably transduced with PDK1 were blotted with the indicated 
antibodies. Tubulin was used as loading control. Protein levels were normalized to the corresponding loading control and expressed as the fold 
change (numbers below the blots) relative to scramble cells
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apoptosis to materialize, additional events are required. 
One of such events is a chemotherapy treatment [42, 
43]. Since dacarbazine has been shown to promote a 
relatively weak apoptotic response in melanoma [44] 
we speculated that combining this cytotoxic insult with 
STAT3 silencing could be a good model to assess the 
contribution of the STAT3/PDK1 pathway on cell death. 
In the first place, we evaluated the effect of dacarbazine 
by assessing cell viability using the Trypan Blue exclu-
sion method. As shown in Fig. 6b, dacarbazine treatment 
induced a significant increase in the number of non-via-
ble cells in WM9-shSTAT3 cells compared with WM9-
scramble cells. This increase was prevented by expression 
of HA-PDK1 (Fig.  6b). These findings were confirmed 
by using the Resazurin reduction assay (Fig.  6c). Next, 
we assessed apoptotic cell death through PI/Annexin V 
labeling and subsequent flow cytometry analysis. Silenc-
ing of STAT3 was not sufficient to induce cell death in 
WM9 cells under normal growing conditions (Additional 
file  3: Figure S3) but significantly increased the amount 
of dead cells (which corresponds to the sum of apoptotic 
plus necrotic cells) compared to WM9-scramble cells 
upon dacarbazine treatment (Fig.  6d). Importantly, this 
increased mortality was prevented by HA-PDK1 expres-
sion (Fig.  6d). To confirm these findings we expressed 
PDK1 in both UACC903 scramble and STAT3 knock-
down cells as was described for WM9. Again, PDK1 
expression significantly blocked the cell death induced by 
STAT3 silencing upon dacarbazine treatment (Fig.  6e). 
Unlike WM9, UACC903 cells expressing PDK1 presented 
a more resistant phenotype than control cells (Fig.  6e). 
Taken together, these results demonstrate that cell death 
triggered by dacarbazine and facilitated by STAT3 deple-
tion is mediated, at least in part, by PDK1 and down-
stream pathways.
One of the critical mechanisms by which STAT3 medi-
ates apoptosis resistance is the upregulation of several 
anti-apoptotic members of the Bcl-2 family [16]. To eval-
uate the involvement of PDK1 in the STAT3-dependent 
regulation of anti-apoptotic proteins we evaluated the 
expression of Bcl2, Mcl1 and Bcl-XL in WM9 cells after 
STAT3 silencing and PDK1 re-expression. The expres-
sion levels of Bcl2, Mcl1 and Bcl-XL were reduced upon 
STAT3 silencing compared to control cells (Fig. 6f, com-
pare lane 1 and 2). As shown in Fig. 6f, expression of HA-
PDK1 restored the expression of the three STAT3 targets 
down-regulated by STAT3 silencing (compare lane 2 and 
4). The effect was pronounced on Bcl-XL and partial on 
Bcl-2 and Mcl1 reflecting slight differences on their regu-
lation by both STAT3 and PDK1 signals. Importantly, 
manipulation of either STAT3 or PDK1 did not affect 
the activity of ERK/MAPK, a signaling pathway that has 
also being implicated in control of Bcl2 family protein 
expression [45]. Taken together, these findings provide 
direct evidence that PDK1 is required for STAT3’s effect 
on apoptosis by regulating the expression of the anti-
apoptotic proteins Bcl2, Bcl-XL and Mcl1.
Discussion
The potential benefits of inhibiting STAT3 signaling have 
long been recognized in the cancer field [46]. Unfortu-
nately, in contrast to the great success of tyrosine kinase 
inhibitors, development of drugs targeting transcription 
factors including STAT3 has lagged behind, mainly due 
to the greater complexity implicated in disrupting pro-
tein–protein or protein–DNA interactions. Recent pieces 
of evidence have shown a new facet of STAT3 in tumori-
genesis emphasizing its status as a promising therapeutic 
target. Work by Liu et  al. [11] and Girotti et  al. [12] in 
melanoma have shown that STAT3 activation is a new 
mechanism of resistance to vemurafenib treatment. In 
addition, Sos et  al. showed that an autocrine IL-6/JAK/
STAT3 pathway contributes to the intrinsic vemurafenib-
resistant phenotype seen in many BRAF-mutant cells 
[14]. Vultur et al. also showed STAT3 activation in resist-
ant cells and revealed that targeting the STAT3 pathway 
prevents the invasive phenotype induced by MEK inhi-
bition [13]. Interestingly, STAT3 activation seems to be 
a general mechanism of acquired resistance since it was 
also observed in cancer cells driven by diverse kinases, 
including EGFR, HER2, ALK, and MET, as well as mutant 
KRAS following treatment with specific inhibitors [47]. 
In this context, it is anticipated that an in-depth under-
standing of STAT3 pathway, its downstream targets and 
their contribution to cancer progression could allow for 
improved therapeutic agents and interventions.
In the current study, we established that STAT3 is con-
stitutively bound to the PDK1 promoter and promotes 
PDK1 transcription in melanoma through at least two 
STAT3 responsive elements. This regulation most likely 
play a particularly relevant role in the altered context of 
a tumor cell by strengthening the phosphorylation and 
activation of AGC kinases including Akt, PKC, and SGK. 
Indeed, overexpression of PDK1 due to an increase in 
gene copy number or protein overexpression have been 
demonstrated in breast cancer and acute myeloid leuke-
mia, among other malignancies [48] and can be of critical 
importance to boost the signal output of upstream altera-
tions such as PTEN, PIK3CA and ERBB2 to Akt [49].
The data presented here provide a mechanistic 
explanation for the well-documented functional asso-
ciation observed between the STAT3 and PI3K/Akt 
signaling pathways in cancer [50]. STAT3 was shown 
to positively regulate Akt phosphorylation [51, 52] and 
indirect evidence has also linked STAT3 to PDK1. Xiao 
et al. have described that atractylenolide-1, a bioactive 
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herb compound from traditional Chinese herbs with 
anti-inflammatory and anti-tumor activities, stimu-
lates ERK phosphorylation and inhibited phosphoryla-
tion and protein expression of STAT3, SP1 and PDK1 
in lung cancer cells [53]. Similarly, the candidate anti-
metastatic agent 6BIO, an indirubin derivative, was 
shown to inhibit phosphorylation of STAT3, GSK3 
and  Thr308 phosphorylation of Akt (the site phospho-
rylated by PDK1) [54]. Similarly, an in  vivo model of 
squamous cell carcinoma driven by constitutive activa-
tion of Src showed increased levels of activated PDK1, 
STAT3, and ERK1/2 in the lesioned tissue [55]. How-
ever, none of these studies have elucidated the precise 
link between STAT3 and PDK1.
Our results showed that STAT3 silencing by itself 
does not significantly affect neither proliferation nor 
cell death of WM9 melanoma cells likely because these 
cells harbor both BRAFV600E mutation and PTEN 
homozygous deletion. However, in the presence of 
dacarbazine, STAT3 silencing significantly increased 
cell death. Notably, overexpression of PDK1 markedly 
reduced dacarbazine sensitivity induced by STAT3 
shRNA. Our data show that PDK1 overexpression res-
cued the expression of Bcl-2, Bcl-xL y Mcl-1 whose 
levels were down-regulated upon STAT3 silencing. 
This result is in agreement with data from Pugazhen-
thi et  al. that showed a PDK1-dependent increase in 
Bcl2 promoter activity in PC12 cells [56]. These results 
indicate that STAT3 can regulate the expression of 
Bcl2 family proteins both directly (by transactivating 
them) and indirectly by modulating PDK1 transcrip-
tion. PDK1, in turn, regulates the activity of AGC 
kinases that could phosphorylate and engage other 
transcription factors in the expression of Bcl2 family 
proteins. It has been documented that Akt regulates 
Bcl2 and Bcl-XL expression by activating CREB [57] 
and NF-κB respectively [57] and SGK1 regulates Mcl-1 
expression through STAT1/STAT2 [58].
This study has established that STAT3 regulates 
PDK1 and have a profound impact on PDK1 down-
stream signaling pathways. The constitutive activity 
of STAT3 in melanoma contributes to increase the 
expression level of PDK1 which, in turn phosphoryl-
ate and activate AGC kinases including Akt, PKC, and 
SGK. These finding provide a mechanistic explanation 
for the association observed in cancer between STAT3 
and PI3K/Akt pathway. Our results also established 
that PDK1 is an important mediator of drug-resistance 
mediated by STAT3 in melanoma. These results add 
further support to both STAT3 and PDK1 as rational 
targets to complement either BRAF-targeted therapy 
in melanoma or chemotherapy in other tumor types.
Additional files
Additional file 1. STAT3β inhibits the luciferase activity driven by PDK1 
promoter.
Additional file 2. Neither STAT3 silencing  nor PDK1 overexpression 
affects WM9 cell proliferation.
Additional file 3. Neither STAT3 silencing nor PDK1 overexpression 
induces changes in apoptosis.
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